Laboratory of Biochemistry, University of Crete Medical School, Heraklion 71003, Greece; Gene Regulation and Genomics group, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology of Hellas, Heraklion 70013, Greece.
Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Metabolism. 2020 Sep;110:154307. doi: 10.1016/j.metabol.2020.154307. Epub 2020 Jul 3.
Aberrant concentration, structure and functionality of High Density Lipoprotein (HDL) are associated with many prevalent diseases, including cardiovascular disease and non-alcoholic fatty liver disease (NAFLD). Mice with liver-specific ablation of Hnf4α (H4LivKO) present steatosis and dyslipidemia by mechanisms that are not completely understood. The aim of this study was to explore the role of liver HNF4A in HDL metabolism and the development of steatosis.
Serum and tissue samples were obtained from 6-weeks old H4LivKO mice and their littermate controls. Liver and serum lipids were measured and HDL structure and functionality were assessed. Global gene expression changes in the liver were analyzed by expression arrays, validations were performed by RT-qPCR and DNA-protein interactions were studied by chromatin immunoprecipitation (ChIP). H4LivKO mice presented liver steatosis, increased liver triglyceride content and decreased concentration of serum total cholesterol, HDL cholesterol, triglycerides, phospholipids and cholesteryl esters. Most classes of phospholipids showed significant changes in species ratio and sphingosine-1-phosphate (S1P) levels were reduced. H4LivKO serum was enriched in the smaller, denser HDL particles, devoid of APOA2 and APOM apolipoproteins, exhibiting decreased activity of paraoxonase-1 but retaining macrophage cholesterol efflux capacity and phospho-AKT activation in endothelial cells. Global gene expression analysis revealed the association of liver HNF4A with known and novel regulators of HDL metabolism as well as NAFLD-susceptibility genes.
HNF4A ablation in mouse liver causes hepatic steatosis, perturbations in HDL structure and function and significant global changes in gene expression. This study reveals new targets of HNF4A involved in HDL metabolism and the development of steatosis and enriches our knowledge on HDL functionality in NAFLD.
异常的高密度脂蛋白(HDL)浓度、结构和功能与许多常见疾病有关,包括心血管疾病和非酒精性脂肪性肝病(NAFLD)。肝脏特异性敲除 Hnf4α 的小鼠(H4LivKO)通过尚未完全阐明的机制出现脂肪变性和血脂异常。本研究旨在探讨肝脏 HNF4A 在 HDL 代谢和脂肪变性发展中的作用。
从 6 周龄的 H4LivKO 小鼠及其同窝对照小鼠中获得血清和组织样本。测量肝脏和血清脂质,并评估 HDL 结构和功能。通过表达谱分析研究肝脏的全基因组基因表达变化,通过 RT-qPCR 进行验证,并通过染色质免疫沉淀(ChIP)研究 DNA-蛋白质相互作用。H4LivKO 小鼠出现肝脏脂肪变性,肝甘油三酯含量增加,血清总胆固醇、HDL 胆固醇、甘油三酯、磷脂和胆固醇酯浓度降低。大多数磷脂类物质的物种比例发生显著变化,鞘氨醇-1-磷酸(S1P)水平降低。H4LivKO 血清富含较小、较密的 HDL 颗粒,缺乏 APOA2 和 APOM 载脂蛋白,对对氧磷酶-1 的活性降低,但保留内皮细胞中巨噬细胞胆固醇流出能力和磷酸化 AKT 的激活。全基因组基因表达分析显示,肝脏 HNF4A 与已知和新的 HDL 代谢调节剂以及 NAFLD 易感性基因相关。
肝脏 HNF4A 敲除导致小鼠肝脂肪变性、HDL 结构和功能紊乱以及基因表达的显著全局变化。本研究揭示了 HNF4A 参与 HDL 代谢和脂肪变性发展的新靶点,并丰富了我们对 NAFLD 中 HDL 功能的认识。